1. Gokhale PC, Zhang C, Newsome J, Pei J, Ahmad I, Rahman A, Dritschilo A, Kasid U (2002) Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome (LErafAON). Clin Cancer Res 8:3611–3621
2. Rudin CM, Marshall JL, Huang CH, Kindler HL, Zhang C, Kumar D, Gokhale PC, Steinberg J, Wanaski S, Kasid UN, Ratain MJ (2004) Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res 10(21):7244–7251
3. Dritschilo A, Huang CH, Rudin CM, Marshall J, Collins B, Dul JL, Zhang C, Kumar D, Gokhale PC, Ahmad A, Ahmad I, Sherman JW, Kasid UN (2006) Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin Cancer Res 12:1251–1259
4. Boudreau HE, Broustas CG, Gokhale PC, Mewani RR, Ahmad I, Kasid U (2006) Inhibition of Raf-1 in human breast cancer cells is associated with decreased expression of BRCC3, a novel cell cycle regulated molecule. 97th annual American Association of Cancer Research Meeting, Washington, DC., Abstract No. 2586
5. Boudreau HE, Broustas CG, Gokhale PC, Kumar D, Mewani RR, Rone JD, Haddad BR, Kasid U (2007) Expression of BRCC3, a novel cell cycle regulated molecule, is associated with increased phospho- ERK and cell proliferation. Int J Mol Med 19:29–39